Klaria announces first dose of its Sumatriptan Alginate Film (KL-00119)
Klaria Pharma Holding AB announced today that the first group of subjects received their first dose in the company’s pivotal Bioequivalence Study of Sumatriptan Alginate Film. The dosing of all 12 subjects in the first group took place on Tuesday, December 15[th].A total of 60 subjects will be dosed in the study. The study has a cross-over design, where all subjects will receive both Sumatriptan Alginate Film as well as the comparator product. The comparator product used in the study has been approved by both the European regulatory authority, EMA, as well as the US regulatory authority,